Thera-SAbDab

BEMARITUZUMAB

>   Structural Summary
TherapeuticBemarituzumab
TargetFGFR2
Heavy ChainQVQLVQSGAEVKKPGSSVKVSCKASGYIFTTYNVHWVRQAPGQGLEWIGSIYPDNGDTSYNQNFKGRATITADKSTSTAYMELSSLRSEDTAVYYCARGDFAYWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCKASQGVSNDVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQHSTTPYTFGQGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-III
Estimated Status (June '19)Active
Recorded Developmental TechnologyPOTELLIGENT Technology
INN Year Proposed2017
INN Year Recommended2018
Companies InvolvedFive Prime Therapeutics, ZAI Lab
Conditions Approvedna
Conditions ActiveGastric cancer, Oesophageal cancer, Solid tumours
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]